Cite
HARVARD Citation
Han, X. et al. (n.d.). 341 Phase I clinical pharmacokinetics, safety and tolerability of simotinib in advanced NSCLC patients with EGFR mutation. European journal of cancer. pp. S67-S68. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Han, X. et al. (n.d.). 341 Phase I clinical pharmacokinetics, safety and tolerability of simotinib in advanced NSCLC patients with EGFR mutation. European journal of cancer. pp. S67-S68. [Online].